Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
1,536 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05337137 | A Study of Nivolumab and Relatlimab in Combination With Bevacizumab in Advanced Liver Cancer(RELATIVITY-106) | completed | Phase 1 / Phase 2 | 83 | Bristol-Myers SquibbINDUSTRY | 15 | Jan 12, 2026 | clinicaltrials |
| NCT05544552 | Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations(SURF301) | active not recruiting | Phase 1 / Phase 2 | 310 | Tyra Biosciences, IncINDUSTRY |
| 4 |
| Jan 12, 2026 |
| clinicaltrials |
| NCT06163430 | A Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia (CARDINAL)(CARDINAL) | recruiting | Phase 1 / Phase 2 | 180 | Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 9 | Jan 12, 2026 | clinicaltrials |
| NCT07334301 | A Multi-Arm, Platform Trial For Relapsed Neuroblastoma(BEACON2) | recruiting | Phase 1 / Phase 2 | 160 | University of BirminghamOTHER | 5 | Jan 12, 2026 | clinicaltrials |
| NCT02442349 | Phase II Single Arm Study of AZD9291 to Treat NSCLC Patients in Asia Pacific(AURA17) | completed | Phase 2 | 171 | AstraZenecaINDUSTRY | 3 | Jan 9, 2026 | clinicaltrials |
| NCT04585815 | Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study) | terminated | Phase 1 / Phase 2 | 34 | PfizerINDUSTRY | 4 | Jan 9, 2026 | clinicaltrials |
| NCT05041257 | Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers(PICCOLO) | completed | Phase 2 | 79 | AbbVieINDUSTRY | 7 | Jan 9, 2026 | clinicaltrials |
| NCT03899792 | A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors(LIBRETTO-121) | active not recruiting | Phase 1 / Phase 2 | 36 | Eli Lilly and CompanyINDUSTRY | 11 | Jan 6, 2026 | clinicaltrials |
| NCT05054725 | Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies | completed | Phase 2 | 47 | Revolution Medicines, Inc.INDUSTRY | 10 | Jan 6, 2026 | clinicaltrials |
| NCT05952037 | A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia | active not recruiting | Phase 2 | 114 | BeOne MedicinesINDUSTRY | 9 | Jan 2, 2026 | clinicaltrials |
| NCT04986852 | Olinvacimab With Pembrolizumab in Patients With mTNBC | terminated | Phase 2 | 19 | PharmAbcineINDUSTRY | 1 | Dec 30, 2025 | clinicaltrials |
| NCT06198426 | A Study of IBI3004 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors | terminated | Phase 1 / Phase 2 | 5 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 2 | Dec 30, 2025 | clinicaltrials |
| NCT05704049 | A Study to Investigate Subcutaneous Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma(IZALCO) | active not recruiting | Phase 2 | 118 | SanofiINDUSTRY | 7 | Dec 29, 2025 | clinicaltrials |
| NCT03993379 | PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors | terminated | Phase 2 | 3 | CytomX TherapeuticsINDUSTRY | 5 | Dec 26, 2025 | clinicaltrials |
| NCT07197827 | A Study of YL242 in Subjects With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 424 | MediLink Therapeutics (Suzhou) Co., Ltd.INDUSTRY | 3 | Dec 24, 2025 | clinicaltrials |
| NCT04154943 | Study of Cemiplimab in Patients With Type of Skin Cancer Stage II to IV Cutaneous Squamous Cell Carcinoma | completed | Phase 2 | 79 | Regeneron PharmaceuticalsINDUSTRY | 3 | Dec 23, 2025 | clinicaltrials |
| NCT06690775 | CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer. | recruiting | Phase 2 | 230 | TORL Biotherapeutics, LLCINDUSTRY | 12 | Dec 23, 2025 | clinicaltrials |
| NCT02854436 | An Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies(Galahad) | completed | Phase 2 | 289 | Janssen Research & Development, LLCINDUSTRY | 15 | Dec 22, 2025 | clinicaltrials |
| NCT02985957 | A Study of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer (CheckMate 650)(CheckMate 650) | completed | Phase 2 | 351 | Bristol-Myers SquibbINDUSTRY | 10 | Dec 22, 2025 | clinicaltrials |
| NCT05499013 | Study to Assess SLN124 in Patients With Polycythemia Vera(SLN) | active not recruiting | Phase 1 / Phase 2 | 69 | Silence Therapeutics plcINDUSTRY | 9 | Dec 19, 2025 | clinicaltrials |
| NCT03534947 | A Study to Evaluate Neoadjuvant Sonidegib Followed by Surgery or Imiquimod in the Management of Basal Cell Carcinoma(SONIB) | completed | Phase 2 | 16 | Melanoma Institute AustraliaOTHER | 1 | Dec 16, 2025 | clinicaltrials |
| NCT04009681 | A Study Evaluating Safety and Therapeutic Activity of THOR-707 in Adult Subjects With Advanced or Metastatic Solid Tumors (THOR-707-101)(HAMMER) | terminated | Phase 1 / Phase 2 | 175 | Synthorx, Inc, a Sanofi companyINDUSTRY | 6 | Dec 15, 2025 | clinicaltrials |
| NCT04811027 | Combination Study With Eftilagimod Alpha (a Soluble LAG-3 Fusion Protein) and Pembrolizumab in Patients With Recurrent or Metastatic HNSCC(TACTI-003) | completed | Phase 2 | 171 | Immutep S.A.S.INDUSTRY | 9 | Dec 11, 2025 | clinicaltrials |
| NCT02374242 | Anti-PD 1 Brain Collaboration for Patients With Melanoma Brain Metastases(ABC) | active not recruiting | Phase 2 | 76 | Melanoma Institute AustraliaOTHER | 1 | Dec 10, 2025 | clinicaltrials |
| NCT04538742 | A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer(DB-07) | active not recruiting | Phase 1 / Phase 2 | 245 | AstraZenecaINDUSTRY | 15 | Dec 8, 2025 | clinicaltrials |
| NCT03377361 | An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Cancer of the Colon or Rectum That Has Spread(CheckMate 9N9) | completed | Phase 1 / Phase 2 | 325 | Bristol-Myers SquibbINDUSTRY | 10 | Dec 3, 2025 | clinicaltrials |
| NCT04704219 | Pembrolizumab Plus Lenvatinib for First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (1L nccRCC) (MK-3475-B61)(KEYNOTE-B61) | completed | Phase 2 | 160 | Merck Sharp & Dohme LLCINDUSTRY | 14 | Dec 3, 2025 | clinicaltrials |
| NCT05626634 | Open-label, Long-term Safety Study of LP352 in Subjects With Developmental and Epileptic Encephalopathy | completed | Phase 2 | 41 | Longboard PharmaceuticalsINDUSTRY | 2 | Dec 3, 2025 | clinicaltrials |
| NCT01582269 | A Study in Recurrent Glioblastoma (GB) | completed | Phase 2 | 158 | Eli Lilly and CompanyINDUSTRY | 10 | Nov 24, 2025 | clinicaltrials |
| NCT07244705 | A Study of ABT-301 Plus Tislelizumab With Bevacizumab in pMMR/Non-MSI-H Locally Advanced or mCRC | recruiting | Phase 1 / Phase 2 | 66 | Anbogen Therapeutics, Inc.INDUSTRY | 2 | Nov 24, 2025 | clinicaltrials |
| NCT04644237 | Trastuzumab Deruxtecan in Participants With HER2-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)(DESTINY-LUNG02) | completed | Phase 2 | 152 | Daiichi SankyoINDUSTRY | 10 | Nov 21, 2025 | clinicaltrials |
| NCT05914116 | A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 862 | DualityBio Inc.INDUSTRY | 4 | Nov 21, 2025 | clinicaltrials |
| NCT01602666 | Chemotherapy Followed by Radiation Therapy in Treating Younger Patients With Newly Diagnosed Localized Central Nervous System Germ Cell Tumors | completed | Phase 2 | 262 | Children's Oncology GroupNETWORK | 5 | Nov 20, 2025 | clinicaltrials |
| NCT06184035 | A Dose Escalation and Expansion Study of [177Lu]Lu-SN201 in Participants With Advanced Cancer(Tumorad) | recruiting | Phase 1 / Phase 2 | 90 | Spago Nanomedical ABINDUSTRY | 1 | Nov 20, 2025 | clinicaltrials |
| NCT03498521 | A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site(CUPISCO) | completed | Phase 2 | 529 | Hoffmann-La RocheINDUSTRY | 33 | Nov 19, 2025 | clinicaltrials |
| NCT04854499 | Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell Carcinoma(ELEVATE HNSCC) | terminated | Phase 2 | 193 | Gilead SciencesINDUSTRY | 11 | Nov 19, 2025 | clinicaltrials |
| NCT03369223 | A Study of BMS-986249 Alone and in Combination With Nivolumab in Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 356 | Bristol-Myers SquibbINDUSTRY | 11 | Nov 18, 2025 | clinicaltrials |
| NCT06170190 | A Multicentre,Study of IBI133 in Subjects WithUnresectable, Locally Advanced or Metastatic SolidTumours | completed | Phase 1 / Phase 2 | 19 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Nov 17, 2025 | clinicaltrials |
| NCT04106492 | Phase 1/2a Study of SQ3370 in Patients With Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 53 | Shasqi, Inc.INDUSTRY | 2 | Nov 14, 2025 | clinicaltrials |
| NCT05643742 | A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies | recruiting | Phase 1 / Phase 2 | 120 | CRISPR Therapeutics AGINDUSTRY | 2 | Nov 14, 2025 | clinicaltrials |
| NCT01878617 | A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma | active not recruiting | Phase 2 | 660 | St. Jude Children's Research HospitalOTHER | 4 | Nov 13, 2025 | clinicaltrials |
| NCT02060188 | A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has Spread(CheckMate142) | completed | Phase 2 | 385 | Bristol-Myers SquibbINDUSTRY | 8 | Nov 6, 2025 | clinicaltrials |
| NCT03539536 | Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer | active not recruiting | Phase 2 | 270 | AbbVieINDUSTRY | 26 | Nov 5, 2025 | clinicaltrials |
| NCT02875548 | A Study to Assess Long-term Safety of Tazemetostat in Adult Participants of All Ages With Any Disease Treated With Tazemetostat in a Previous Clinical Study(TRuST) | completed | Phase 1 / Phase 2 | 58 | Epizyme, Inc.INDUSTRY | 7 | Nov 4, 2025 | clinicaltrials |
| NCT04958785 | Study of Magrolimab Combination Therapy in Patients With Non-Surgically Removable Locally Advanced or Metastatic Triple-Negative Breast Cancer(ELEVATE TNBC) | terminated | Phase 2 | 92 | Gilead SciencesINDUSTRY | 6 | Nov 4, 2025 | clinicaltrials |
| NCT06249048 | Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab | recruiting | Phase 1 / Phase 2 | 108 | Strand Therapeutics Inc.INDUSTRY | 2 | Oct 29, 2025 | clinicaltrials |
| NCT04700072 | Substudy 02D: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Melanoma Brain Metastasis (MK-3475-02D/KEYMAKER-U02) | completed | Phase 1 / Phase 2 | 56 | Merck Sharp & Dohme LLCINDUSTRY | 8 | Oct 28, 2025 | clinicaltrials |
Data updated 24 days agoSource updated unknownsource: clinicaltrials